Signs Of Hope But Obstacles Remain For Swiss Device MRA With EU
Executive Summary
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.
You may also be interested in...
‘A Divorce But We Weren’t Even Married’ – Swiss Medtech Expects No EU MRA Before May
A last-minute solution to the unresolved EU MRA issue is unlikely, so local manufacturers must prepare for Switzerland to be a “third country” to the EU after the MDR comes fully into force.
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.
UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment
Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.